Serum levels of renin-angiotensin system components in acute stroke patients

Geriatrics and Gerontology International

Volumn 14, Issue 4, 2014, Pages 793-798

  Mogi, Masaki ^a   Kawajiri, Masakazu ^b   Tsukuda, Kana ^a   Matsumoto, Shoji ^b   Yamada, Takeshi ^b   Horiuchi, Masatsugu ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SAISEIKAI FUKUOKA GENERAL HOSPITAL   (Japan)

Author keywords

Angiotensin converting enzyme2; AngiotensinII; Cardioembolism; Renin angiotensin system; Stroke outcome

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE; RENIN; BIOLOGICAL MARKER;

AGED; ANGIOTENSIN BLOOD LEVEL; ARTICLE; ATHEROSCLEROSIS; ATHEROTHROMBOTIC INFARCTION; BRAIN INFARCTION; BRAIN ISCHEMIA; CARDIOEMBOLIC STROKE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DISEASE CLASSIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOSPITAL ADMISSION; HUMAN; LACUNAR STROKE; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OCCLUSIVE CEREBROVASCULAR DISEASE; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; ACUTE DISEASE; BLOOD; FOLLOW UP; PHYSIOLOGY; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; STROKE;

ACUTE DISEASE; AGED; ANGIOTENSIN II; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDYL-DIPEPTIDASE A; RENIN-ANGIOTENSIN SYSTEM; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STROKE;

EID: 84931835689     PISSN: 14441586     EISSN: 14470594     Source Type: Journal    
DOI: 10.1111/ggi.12167     Document Type: Article

References (22)

1. Schrader J, Luders S, Kulschewski A etal. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36: 1218-1226.
2. Kawajiri M, Mogi M, Higaki N etal. Angiotensin-converting enzyme (ACE) and ACE2 levels in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler 2009; 15: 262-265.
3. Kawajiri M, Mogi M, Osoegawa M etal. Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler 2008; 14: 557-560.
4. Fuentes B, Fernandez-Dominguez J, Ortega-Casarrubios MA, SanJose B, Martinez-Sanchez P, Diez-Tejedor E. Treatment with angiotensin receptor blockers before stroke could exert a favourable effect in acute cerebral infarction. J Hypertens 2010; 28: 575-581.
5. Schrader J, Luders S, Kulschewski A etal. The access study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003; 34: 1699-1703.
6. Adams HP, Jr, Bendixen BH, Kappelle LJ etal. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of org 10172 in acute stroke treatment. Stroke 1993; 24: 35-41.
7. Cardiogenic brain embolism. Cerebral Embolism Task Force. Arch Neurol 1986; 43: 71-84.
8. Kawajiri M, Mogi M, Higaki N etal. Reduced angiotensin II levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neurol Scand 2009; 119: 341-344.
9. Santos RA, Ferreira AJ, Verano-Braga T, Bader M. Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. J Endocrinol 2013; 216: R1-R17.
10. Wang Y, Moreira Mda C, Heringer-Walther S etal. Plasma ACE2 activity is an independent prognostic marker in Chagas' disease and equally potent as BNP. J Card Fail 2010; 16: 157-163.
11. Epelman S, Shrestha K, Troughton RW etal. Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes. J Card Fail 2009; 15: 565-571.
12. Zhong J, Basu R, Guo D etal. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 2010; 122: 717-728.
13. Soro-Paavonen A, Gordin D, Forsblom C etal. Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications. J Hypertens 2012; 30: 375-383.
14. Gonzalez GE, Seropian IM, Krieger ML etal. Effect of early versus late AT1 receptor blockade with losartan on postmyocardial infarction ventricular remodeling in rabbits. Am J Physiol Heart Circ Physiol 2009; 297: H375-H386.
15. Nielsen HM, Londos E, Minthon L, Janciauskiene SM. Soluble adhesion molecules and angiotensin-converting enzyme in dementia. Neurobiol Dis 2007; 26: 27-35.
16. Epelman S, Tang WH, Chen SY, Van Lente F, Francis GS, Sen S. Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system. J Am Coll Cardiol 2008; 52: 750-754.
17. Hosomi N, Nishiyama A, Ban CR etal. Angiotensin type 1 receptor blockage improves ischemic injury following transient focal cerebral ischemia. Neuroscience 2005; 134: 225-231.
18. Inaba S, Iwai M, Tomono Y etal. Exaggeration of focal cerebral ischemia in transgenic mice carrying human renin and human angiotensinogen genes. Stroke 2009; 40: 597-603.
19. Al-Merani SA, Brooks DP, Chapman BJ, Munday KA. The half-lives of angiotensin II, angiotensin II-amide, angiotensin III, Sar1-Ala8-angiotensin II and renin in the circulatory system of the rat. J Physiol 1978; 278: 471-490.
20. Matsushita T, Isobe N, Kawajiri M etal. Csf angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity. J Neurol Sci 2010; 295: 41-45.
21. Wosik K, Cayrol R, Dodelet-Devillers A etal. Angiotensin ii controls occludin function and is required for blood brain barrier maintenance: relevance to multiple sclerosis. J Neurosci 2007; 27: 9032-9042.
22. Min LJ, Mogi M, Shudou M etal. Peroxisome proliferator-activated receptor-gamma activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice. Hypertension 2012; 59: 1079-1088.